28 completed, 6 recruiting, 5 not yet recruiting, 4 active not recruiting. 22 Phase 3, 6 Phase 1, 5 Phase 2, 2 Not applicable, 2 Phase 4.
Follow Mixed Dyslipidemia: new trials by email Literature Review of Mixed Dyslipidemia trials Research Report on Mixed Dyslipidemia
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Phase 2 Dose-Finding Study Evaluating the Efficacy and Safety of EDP167 in Adults With Mixed Dyslipidemia EDP167 100mg, EDP167 200mg, EDP167 300mg - Mixed Dyslipidemia | Phase 2 | Not yet recruiting | Eddingpharm (Zhuhai) Co., Ltd. | 144 | 2026-11-01 | 2026-09-02 |
| A Study of Bempedoic Acid/Ezetimibe/High-intensity Statin in Patients Without Cardiovascular Events Bempedoic acid, Ezetimibe, Rosuvastatin - Coronary Atherosclerosis, Mixed Dyslipidemia | Phase 3 | Not yet recruiting | Daiichi Sankyo | 103 | 2026-09-30 | 2026-09-29 |
| Phase 2 Clinical Study of MWX203 Injection Alone or in Combination With Inclisiran Sodium Injection in Patients With Mixed Dyslipidemia MWX203, Inclisiran Sodium Injection, Placebo - Mixed Dyslipidemia | Phase 2 | Recruiting | Shanghai Minwei Biotechnology Co., Ltd | 216 | 2026-09-25 | 2026-09-08 |
| Phase 3 Clinical Study Evaluating Efficacy, Safety, and Tolerability of Obicetrapib Vs Bempedoic Acid to Treat Dyslipidemia in Adults With Primary Non-familial Hypercholesterolemia or Mixed Dyslipidemia at High to Very High Cardiovascular Risk, During a Treatment Period of Approximately 84 Days Obicetrapib 10 mg/Bempedoic Acid Placebo, Bempedoic Acid 180mg/Placebo Obicetrapib - Mixed Dyslipidemia, Hypercholesterolaemia | Phase 3 | Recruiting | A. Menarini International Licensing S.A. | 426 | 2026-05-06 | 2026-06-09 |
| A Study of Bempedoic Acid or Its Single-pill Combination Therapy With Ezetimibe in Patients With Primary Hypercholesterolaemia or Mixed Dyslipidaemia Combination of bempedoic acid and ezetimibe - Primary Hypercholesterolaemia, Mixed Dyslipidemia | Recruiting | Daiichi Sankyo | 2120 | 2026-03-03 | 2026-10-19 | |
| ATLANTIS Trial: Phospholipid Omega-3 Versus Conventional Omega-3 Phospholipid Omega-3, Triglyceride Omega-3 - Mixed Dyslipidemia | Not applicable | Not yet recruiting | Fundación del Caribe para la Investigación Biomédica | 105 | 2026-03-01 | 2026-02-10 |
| A Study to Evaluate the Effect of Food on the Pharmacokinetic Characteristics and Safety Profile of AD-117 in Healthy Adult Volunteers AD-117 - Mixed Dyslipidemia, Food Effect Study of AD-117 | Phase 1 | Completed | Addpharma Inc. | 60 | 2026-02-10 | 2026-07-15 |
| A Study to Compare to PK Characteristics and Safety Profiles Between AD-117 and AD-117A AD-117, AD-117A - Mixed Dyslipidemia | Phase 1 | Not yet recruiting | Addpharma Inc. | 60 | 2025-12-01 | 2025-12-04 |
| Clinical Trial to Evaluate the Safety, Pharmacokinetic Characteristics of DW5124 and DW5124-R, and the Effect of Food on DW5124 in Healthy Adult Volunteers DW5124, DW5124-R - Mixed Dyslipidemia | Phase 1 | Completed | Daewon Pharmaceutical Co., Ltd. | 55 | 2025-05-08 | 2026-01-06 |
| The Food Effect on PK Characteristics and Safety Profiles of PA-111 PA-111 - Mixed Dyslipidemia | Phase 1 | Not yet recruiting | Addpharma Inc. | 40 | 2025-05-01 | 2025-05-16 |
| Clinical Trial to Evaluate the Efficacy and Safety of Combination Therapy of DW5421A/DW5421B Compared to Monotherapy of DW5421A DW5421A, DW5421B Placebo, DW5421B - Primary Hypercholesterolemia, Mixed Dyslipidemia | Phase 3 | Completed | Daewon Pharmaceutical Co., Ltd. | 184 | 2025-04-21 | 2026-03-06 |
| A Study to Compare to PK Characteristics and Safety Profiles Between PA-111 and PA-111A PA-111, PA-111A - Mixed Dyslipidemia | Phase 1 | Recruiting | Addpharma Inc. | 48 | 2025-04-01 | 2025-04-17 |
| A Study of Bempedoic Acid in Combination With Ezetimibe and Either Rosuvastatin or Atorvastatin in Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia Bempedoic acid, Ezetimibe, Rosuvastatin - Primary Hypercholesterolemiia, Mixed Dyslipidemia | Active not recruiting | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 2000 | 2025-02-12 | 2026-09-30 | |
| A Study to Assess the Real-World Effectiveness of Inclisiran and PCSK9 mAbs in Chinese Hypercholesterolemia Adult Patients Hypercholesterolemia, Mixed Dyslipidemia | Completed | Novartis Pharmaceuticals | 11991 | 2025-01-23 | 2026-02-17 | |
| A Clinical Study to Evaluate the Safety and Effectiveness of Inclisiran Sodium in Indian Patients With Primary Hypercholesterolemia or Mixed Dyslipidemia inclisiran - Primary Hypercholesterolemia, Mixed Dyslipidemia | Phase 4 | Completed | Novartis Pharmaceuticals | 65 | 2024-11-12 | 2026-06-23 |
| A Study to Evaluate the Efficacy and Safety of Fixed-Dose Combination of Pitavastatin/Ezetimib Primary Hypercholesterolemia, Mixed Dyslipidemia | Recruiting | Boryung Pharmaceutical Co., Ltd | 8606 | 2024-03-15 | 2025-09-12 | |
| A Study in Patients With Mixed Dyslipidemia BW-00112 - Mixed Dyslipidemia | Phase 2 | Active not recruiting | Shanghai Argo Biopharmaceutical Co., Ltd. | 145 | 2024-02-28 | 2026-01-13 |
| Treatment With Bempedoic Acid And/Or Its Fixed-dose Combination With Ezetimibe in Routine Clinical Practice in Patients With Primary Hypercholesterolemia Or Mixed Dyslipidemia Bempedoic acid and/or its fixed dose combination with ezetimibe - Primary Hypercholesterolemia, Mixed Dyslipidemia | Withdrawn | Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company | 2023-09-01 | 2023-12-06 | ||
| Study Evaluating LDL-C Change and Adherence to Inclisiran Lipid-lowering Therapy in ASCVD Inclisiran - Primary Hypercholesterolemia, Mixed Dyslipidemia | Active not recruiting | Novartis Pharmaceuticals | 847 | 2022-09-12 | 2026-09-24 | |
| A Study to Evaluate the Efficacy and Safety of AD-218 AD-218, AD-218A - Mixed Dyslipidemia | Phase 3 | Recruiting | Addpharma Inc. | 520 | 2022-07-27 | 2025-02-05 |
Showing 20 of 50. Sign in to see all of them.
Hypercholesterolemia (14) · Dyslipidemias (8) · Coronary Disease (5) · Diabetes Mellitus (2) · Diabetes Mellitus, Type 2 (2) · Hyperlipidemias (2) · Coronary Artery Disease (1) · Kidney Failure, Chronic (1) · Renal Insufficiency (1)
Lipid Metabolism Disorders (23) · Metabolic Diseases (23) · Nutritional and Metabolic Diseases (23) · Dyslipidemias (15) · Hyperlipidemias (14) · Cardiovascular Diseases (6) · Heart Diseases (6) · Myocardial Ischemia (6) · Vascular Diseases (6) · Endocrine System Diseases (2) · Glucose Metabolism Disorders (2) · Arterial Occlusive Diseases (1) · Arteriosclerosis (1) · Chronic Disease (1) · Coronary Disease (1)
Atorvastatin (8) · Simvastatin (8) · Ezetimibe (7) · 2-(4-(4-chlorobenzoyl)phenoxy)-2-methylpropanoic acid (6) · Rosuvastatin Calcium (5) · evolocumab (5) · 8-hydroxy-2,2,14,14-tetramethylpentadecanedioic acid (4) · MK-0524 (4) · ALN-PCS (3) · Fenofibrate (3) · Fluvastatin (2) · Niacin (2) · fenofibric acid (2) · Berberine (1) · Bezafibrate (1)
Abbott (7) · Addpharma Inc. (5) · Amgen (5) · Merck Sharp & Dohme LLC (5) · Daiichi Sankyo Europe, GmbH, a Daiichi Sankyo Company (4) · Novartis Pharmaceuticals (4) · Arrowhead Pharmaceuticals (2) · Daewon Pharmaceutical Co., Ltd. (2) · Daiichi Sankyo (2) · Novartis (2) · A. Menarini International Licensing S.A. (1) · Boryung Pharmaceutical Co., Ltd (1) · Eddingpharm (Zhuhai) Co., Ltd. (1) · Fundación del Caribe para la Investigación Biomédica (1) · Hanlim Pharm. Co., Ltd. (1)
United States (17) · South Korea (9) · China (6) · Canada (5) · Germany (4) · Italy (4) · Spain (4) · Austria (3) · Belgium (3) · Switzerland (3) · United Kingdom (3) · Australia (2) · Mexico (2) · New Zealand (2) · Poland (2)
Heebaek Park (1) · Joseph B Muhlestein, MD (1) · Kevin C Maki, PhD (1) · Kyu Chang Won, M.D., Ph.D (1) · Maureen Kelly, MD (1) · Roopal Thakkar, MD (1) · Yuqiong Li, Master (1)
PMID 18783301, PMID 20136164, PMID 20573750, PMID 22263674, PMID 16843192, PMID 18678300, PMID 18996523, PMID 19995098, PMID 20518948, PMID 20934572, PMID 21174145, PMID 21401833, PMID 22500948, PMID 24328357, PMID 24998014, PMID 26922296, PMID 27066336, PMID 30953107, PMID 36435949, PMID 38682459, PMID 38804517, PMID 38809174, PMID 42496147
2025 (2), 2015 (1)